An In silico model-based feasibility assessment of erlotinib long-acting injectable formulation for the management of metastatic non-small cell lung cancer
, the prototype formulations required a monthly dose of 300 mg and a three-month dose of 1200 mg, both with intermediate-release profiles.The semimechanistic PBPK model successfully predicted the optimal dose and release profile. The results provided valuable insights for polymer grade selection and drug-to-polymer ratio optimisation.
Authors
- Rajkumar Malayandi (ORCID: https://orcid.org/0000-0003-1435-6115)
- Adarsh Malgave (ORCID: https://orcid.org/0009-0007-8970-7000)
- Anumol Joseph (ORCID: https://orcid.org/0009-0000-8802-0089)
- Sideequl Akbar (ORCID: https://orcid.org/0009-0000-2371-3239)
- Rutuja Suryawanshi (ORCID: https://orcid.org/0009-0003-2015-8649)
Institutions
- National Institute of Pharmaceutical Education and Research (IN)
Publication Details
- Journal
- Xenobiotica
- Published
- 2026-04-22
- DOI
- https://doi.org/10.1080/00498254.2026.2661623
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00